Statement: 2% of the primary trial patients had Recurrence-free Survival < 3 years.
Primary_evidence: Outcome Measurement:    Recurrence-free Survival   Recurrence-free survival curves will be plotted for subjects treated with stage I and II disease.   Time frame: Time from the start of treatment to recurrence, second malignancy, or death as a first event, assessed up to 3 years Results 1:    Arm/Group Title: Treatment (Chemotherapy With or Without Maintenance Therapy)   Arm/Group Description: SYSTEMIC CHEMOTHERAPY: Patients receive cyclophosphamide IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.   MAINTENANCE THERAPY (Her-2 neu positive patients): Patients receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity.   cyclophosphamide, paclitaxel, trastuzumab: Given IV   Overall Number of Participants Analyzed: 100   Measure Type: Number   Unit of Measure: percentage of subjects  98        (92.2 to 99.5)